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Environmental tobacco smoke (ETS) expo-
sure is widespread, affecting the majority of
U.S. adults (1–3). A complex mixture of over
4,000 chemical compounds, ETS contains
potent respiratory irritants such as sulfur diox-
ide, ammonia, formaldehyde, and acrolein
(1,4). As a consequence, ETS exposure could
negatively affect adult pulmonary function.
Although ETS exposure during early life
appears to attenuate the development of peak
lung function (1), the impact of ongoing
exposure on pulmonary function during
adulthood has not been clearly determined.
Because adults with established asthma
have chronic respiratory disease, they may be
particularly susceptible to adverse health
effects of ETS exposure. Reﬂecting this view,
national asthma guidelines recommend that
persons with asthma avoid ETS exposure
(5). Clearly, understanding the impact of
ETS exposure on health status among adult
asthmatics has important clinical and public
policy implications. Despite the importance
of this question, existing data on the effect of
ETS exposure on adults with asthma are sur-
prisingly limited. The few previous epidemi-
ologic studies in adults have suggested a
relationship between ETS exposure and
greater respiratory symptoms, medication
use, and health care utilization for asthma
(6–9). The effects of ETS exposure on pul-
monary function among adults with asthma
have not been well characterized.
Previous reports using data from the pop-
ulation-based Third National Health and
Nutrition Examination Survey (NHANES
III) have reported the prevalence of ETS
exposure (2,10) and effects of ETS on child-
hood respiratory symptoms and pulmonary
function (11). The present study examines
the cross-sectional relationship between
serum cotinine, a biomarker of ETS expo-
sure, and pulmonary function in the general
population of nonsmoking U.S. adults. The
analysis also elucidated the speciﬁc impact of
ETS exposure among adults with current
asthma, a potentially susceptible group. 
Methods
Overview. In the analysis I used data from
NHANES III, which was conducted by the
National Center for Health Statistics of the
U.S. Centers for Disease Control and
Prevention between 1988 and 1994 (12). In
the present study, a stratified, multistage
probability design was used to select a
representative sample of the civilian, nonin-
stitutionalized U.S. population. Extensive
interviews, including questions on demo-
graphic and health information, were con-
ducted with participants in their households.
In specially equipped mobile examination
centers or their homes, participants under-
went a standardized examination, which
included physical examination, pulmonary
function testing, and blood sampling. In this
study, I examined the cross-sectional associa-
tion between ETS exposure and pulmonary
function among nonsmoking U.S. adults,
with a particular focus on adults with
asthma. The study was approved by the
National Center for Health Statistics
Institutional Review Board.
Study sample. The present study
included nonsmoking adult NHANES III
participants ≥ 17 years of age whose serum
cotinine measurements and spirometry data
were available. Of the 20,050 adult partici-
pants, I excluded 4,990 persons who indi-
cated current smoking and an additional
3,639 subjects who did not undergo spirom-
etry, had unreliable spirometry results, or
were missing serum cotinine measurements.
I excluded another 840 subjects who had
serum cotinine levels of ≥ 14 ng/mL, sug-
gesting active current personal smoking
(13,14). The present study sample includes
10,581 adult nonsmokers.
Classification of asthma. The survey
interviews ascertained selected chronic health
conditions, including asthma. Subjects were
asked whether they had ever received a physi-
cian diagnosis of asthma: “Has a doctor ever
told you that you had asthma?” Respondents
who indicated an affirmative answer were
then asked if they currently had the condi-
tion: “Do you still have asthma?” In this
study, adults with asthma were defined as
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The impact of environmental tobacco smoke (ETS) exposure on adult pulmonary function has
not been clearly determined. Because adults with asthma have chronic airway inﬂammation, they
may be a particularly susceptible group. Using data from the Third National Health and
Nutrition Examination Survey (NHANES III), I examined the cross-sectional relationship
between serum cotinine, a biomarker of ETS exposure, and pulmonary function among 10,581
adult nonsmokers and 440 nonsmoking adults with asthma whose cotinine and spirometry data
were available. I generated residuals, which are observed minus predicted values (based on Crapo
equations), for forced expiratory volume in 1 sec (FEV1), forced vital capacity (FVC), and
FEV1/FVC ratio to adjust for age, sex, and height. In addition, I used multivariate linear regres-
sion to control for sociodemographic characteristics and previous smoking history. Most adults
with and without asthma had detectable serum cotinine levels, indicating recent ETS exposure
(85.7% and 83.4%, respectively). Among nonsmoking male participants, I found no evidence
that ETS exposure was related to decreased pulmonary function. In the nonsmoking female stra-
tum, the highest cotinine tertile was associated with a lower FEV1 [–100 mL; 95% confidence
interval (CI), –143 to –56 mL], FVC (–119 mL; 95% CI, –168 to –69 mL), and FEV1/FVC ratio
(–1.77%; 95% CI, –2.18% to –1.36%). Among women with asthma, the highest cotinine tertile
was also associated with decreased FEV1 (–261 mL; 95% CI, –492 to –30 mL), FVC (–291 mL;
95% CI, –601 to 20 mL), and FEV1/FVC ratio (–1.6%; 95% CI, –3.3% to 0.19%). In conclu-
sion, ETS exposure is associated with decreased pulmonary function in adult females, especially
those with asthma. This analysis should provide further impetus for public policies that promote
smoke-free environments. Key words: asthma, environmental tobacco smoke, respiratory function
tests, tobacco smoke pollution. Environ Health Perspect 110:765–770 (2002). [Online
14 June 2002]
http://ehpnet1.niehs.nih.gov/docs/2002/110p765-770eisner/abstract.htmlrespondents who reported current asthma.
To reduce misclassification with smoking-
related chronic obstructive pulmonary dis-
ease, asthma was further deﬁned by excluding
those subjects who also reported ever having
a physician diagnosis of emphysema (15,16).
Assessment of ETS exposure. Serum coti-
nine, a metabolite of nicotine, is a widely
used and speciﬁc biomarker of ETS exposure
(1). Because the half-life of cotinine ranges
from 7 to 40 hr among nonsmokers exposed
to ETS, cotinine reﬂects exposure during the
previous 3–4 days (17,18). Using previously
described methods, serum cotinine levels
were measured using HPLC/atmospheric-
pressure chemical ionization tandem mass
spectrometry (19). The limit of detection for
this method is 0.05 ng/mL.
Self-reported home and work ETS expo-
sure were ascertained by the survey inter-
view. Domestic ETS exposure was deﬁned as
an afﬁrmative answer to the question “Does
anyone who lives here smoke cigarettes in
the home?” Respondents were also asked
about ETS exposure at work: “At work, how
many hours per day are you close enough to
people who smoke so that you can smell the
smoke?” Based on this question, work ETS
exposure was deﬁned as ≥ 1 hr/day.
Pulmonary function measurement.
Spirometry was performed according to the
1987 American Thoracic Society recommen-
dations (20). Examinees performed five to
eight forced expiratory maneuvers. To clas-
sify tests for reliability, two senior quality
technicians at the spirometry quality control
center reviewed all tests (19). In the present
analysis, we included only reliable test results.
Smoking. Personal cigarette smoking was
ascertained using standard questions devel-
oped for the National Health Interview
Survey. In this analysis, previous smoking was
deﬁned as an afﬁrmative answer to the ques-
tion “Have you smoked at least 100 cigarettes
during your entire life?” and a negative answer
to the question “Do you smoke cigarettes
now?” (21). Previous research indicates that
serum cotinine levels of ≥ 14 ng/mL are most
consistent with personal smoking (13,14), so
subjects who indicated no current smoking
but had serum cotinine levels greater than this
level were reclassiﬁed as current smokers and
excluded from analysis.
Other demographic and personal charac-
teristics. The demographic and personal char-
acteristics that are potentially related to ETS
exposure and pulmonary function were exam-
ined. I chose education as a key socioeco-
nomic indicator, which was ascertained as the
highest grade or year of school completed.
Because income can be a cause or result of
health status, I performed the analyses with
and without controlling for income. Low
family income was defined using a survey
item that ascertained whether combined fam-
ily income from all sources was more than or
less than $20,000 during the past 12 months.
The survey ascertained race/ethnicity in a
standardized manner. For this analysis, I
deﬁned race/ethnicity as white, non-Hispanic,
and other categories.
Statistical analysis. Statistical analysis
was performed using SAS, version 6.12 (SAS
Institute, Cary, NC) and SUDAAN, version
7.5 (Research Triangle Institute, Research
Triangle Park, NC). In all analyses, I used
sampling weights to adjust for unequal prob-
abilities of selection and to account for non-
response. SUDAAN was used to calculate
variance estimates that account for the com-
plex survey design (22).
For bivariate comparisons, I used linear
regression analysis for normally distributed
continuous variables and the chi-square test
for categorical variables. The prevalence of
ETS exposure among persons with and with-
out asthma was evaluated using several expo-
sure measures: any detectable serum cotinine,
self-reported domestic exposure, and self-
reported work exposure. Intensity of ETS
exposure was based on serum cotinine level.
I determined predicted pulmonary func-
tion values using the Crapo predictive equa-
tions based on age, height, and sex (23). For
adults with asthma, I also applied the alterna-
tive Hankinson predictive equations, which
were derived from lifelong nonsmoking
NHANES III participants without any
reported history of asthma, other respiratory
diseases, or respiratory symptoms (24). These
predictive equations are based on age, sex,
height, and race/ethnicity. Because these
equations were derived from a group of
NHANES III participants that substantially
overlaps with the total nonsmoking group in
this analysis, these equations were only
applied to analyses restricted to adults with
asthma. Residuals, which are observed minus
predicted values, were generated for forced
expiratory volume in 1 sec (FEV1), forced
vital capacity (FVC), and FEV1/FVC ratio to
adjust for age, sex, and height (and race/eth-
nicity, for the Hankinson equations).
The analytic aim was to determine the
cross-sectional association between ETS
exposure, as measured by serum cotinine
level, and each pulmonary function residual.
To assess this exposure–outcome relation-
ship, I examined three groups of subjects:
total group of adult nonsmoking subjects,
adults who never smoked, and nonsmoking
adults with asthma. Because the results
appeared to differ by sex, all analyses were
stratiﬁed by sex.
In each group, multivariate linear regres-
sion analysis was conducted. As a predictor
variable, I evaluated serum cotinine both as
tertiles (11) and as a continuous variable.
For each pulmonary function outcome, I
examined the impact of cotinine level on the
residual pulmonary function measurement,
which adjusts for age, sex, and height. I then
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Table 1. Demographic and personal characteristics of nonsmoking adult NHANES III participants with
and without asthma.
Adults with  Adults without p-Value for
Variable asthma asthma difference
Sample size (unweighted) 440 10,141 —
Estimated population (weighted) 4,881,125 112,236,176 —
Age (mean, SE) 42.3 (0.91) 44.6 (0.53) 0.012
Sex (% female) 66.3 55.7 0.033
Race/ethnicity (% white) 75.6 76.0 0.87
Low income (%)a 30.3 27.8 0.53
Education (mean years, SE) 12.9 (0.25) 13.0 (0.12) 0.61
Previous cigarette smoking (%) 34.9 32.6 0.53
FEV1 (mean, SE) 2.79 (0.07) 3.02 (0.03) < 0.0001
FVC (mean, SE) 3.80 (0.10) 4.01 (0.03) 0.049
FEV1/FVC ratio (%) 73 (0.8) 80 (0.2) < 0.0001
Sample included all nonsmoking adults ≥ 17 years of age who had serum cotinine measurements and reliable spirometry
results. 
aTotal annual family income < $20,000. 
Table 2. Prevalence of exposure (95% CI) and intensity of exposure (median, 25th–75th IQR) to ETS among
adult nonsmokers by asthma status.
Adults Adults 
Prevalence measure with asthma without asthma p-Value
Detectable cotinine level (%) 85.7 (80.5–90.9) 83.4 (81.1–85.7) 0.38
Intensity of ETS exposure  0.19 (0.08–0.58) 0.16 (0.07–0.42) 0.92
[median cotinine level (ng/mL), 25th–75th IQR]
Self-reported domestic exposure (%) 15.8 (10.7–21.0) 14.6 (13.1–16.1) 0.63
(lives with a smoker)
Self-reported work exposure (%) 25.8 (18.8–32.8) 20.4 (18.4–22.5) 0.11
(close enough to smell smoke ≥ 1 hr/day)
IQR, interquartile range.performed multivariate linear regression to
control for the potential confounding effects
of previous smoking history, race/ethnicity,
and socioeconomic status (education level
and low income). Because income can be the
cause or result of impaired health status,
regression models with and without income
were considered. Because the results were
similar, only the analyses that include
income are presented. I also examined previ-
ous smoking in terms of cumulative expo-
sure (pack-years), which did not appreciably
affect the results (data not presented).
To further ensure that the highest coti-
nine tertile was not composed of intermit-
tent personal smokers, I repeated all analyses
using a lower serum cotinine cutoff of ≥ 10
ng/mL. This additional restriction affected
< 0.5% of subjects in each group: n = 50
nonsmokers, n = 26 never smokers, and n =
1 adult with asthma. I found no appreciable
change in the results (data not shown).
Results
Demographic characteristics. After exclusions,
the study sample included 440 nonsmoking
adults with current self-reported physician-
diagnosed asthma, which represents 4.9 mil-
lion adults in the United States. Among the
nonsmoking study sample, the prevalence of
current asthma was 4.4% [95% confidence
interval (CI), 3.7–5.0%]. Compared to adults
without asthma, those with asthma were
younger (mean age, 44.6 vs. 42.3 years), were
more likely to be female (66.3% vs. 55.7%),
and had lower pulmonary function measure-
ments (Table 1). I found no statistical differ-
ences in race/ethnicity, previous personal
cigarette smoking history, or socioeconomic
status (educational attainment and proportion
with low income).
ETS exposure. Adults with and without
asthma had similar prevalence and intensity
of ETS exposure (p > 0.10; Table 2). Most
adults with asthma had detectable serum
cotinine levels, indicating recent ETS expo-
sure (85.7%). The prevalence of exposure
was similar to those without asthma (83.4%).
I also found no differences in self-reported
domestic ETS exposure (i.e., lives with a
smoker) or self-reported work exposure (i.e.,
reports being close enough to smell smoke at
work ≥ 1 hr/day). Compared to adults with-
out asthma, adults with asthma had similar
ETS exposure intensity (median cotinine,
0.19 vs. 0.16 ng/mL).
Self-reported ETS exposure was related
to serum cotinine level. The number of
smokers at home was moderately correlated
with serum cotinine (Spearman rank correla-
tion = 0.44, p < 0.0001). Reported daily
duration of workplace ETS exposure was
also associated with cotinine level (Spearman
r = 0.30, p < 0.0001).
ETS exposure and pulmonary function
among adult nonsmokers. Among 10,581
adult nonsmokers, which represent 112.2
million U.S. adults, the association between
ETS exposure and pulmonary function var-
ied by sex. In the male stratum, the medium
and high cotinine tertiles were associated
with a decreased FEV1/FVC ratio compared
to the lowest tertile (Table 3). When treated
as a continuous variable, higher cotinine lev-
els were also related to decreased FEV1/FVC
ratio. In analysis adjusting for age and
height, I found no statistical relationship
between cotinine level and FEV1 or FVC.
After controlling for race/ethnicity, previous
smoking history, and socioeconomic indica-
tors (education level and low income), the
medium cotinine tertile was associated with
a greater FEV1 and FVC compared to the
lowest exposure group (mean increment, 78
and 94 mL, respectively). Despite this ﬁnd-
ing, I found no statistical association
between the highest cotinine tertile and
either FEV1 or FVC.
In the female stratum, cotinine levels were
negatively associated with every measure of
pulmonary function (Table 3). Adjusting for
age and height, the medium and highest coti-
nine tertiles were related to decreased FEV1,
FVC, and FEV1/FVC ratio. In multivariate
analysis controlling for additional covariates,
the highest cotinine tertile was statistically
associated with a lower FEV1 (–100 mL; 95%
CI, –143 to –56 mL), FVC (–119 mL; 95%
CI, –168 to –69 mL), and FEV1/FVC ratio
(–1.77%; 95% CI, –2.18% to –1.36%). As a
continuous variable, greater cotinine levels
were also related to decreased FEV1, FVC,
and FEV1/FVC ratio (Table 3).
When the sample was further restricted
to adults who had never smoked, I observed
the same pattern of results (Table 4). Among
male adults, the medium and highest coti-
nine tertiles were associated with decreased
FEV1/FVC ratio. Although the medium coti-
nine tertile was related to a higher FEV1 and
FVC in the multivariate analysis, I found no
statistical relation between the highest tertile
and either spirometric measure. In the female
stratum, the medium and highest cotinine
tertiles were associated with decreased levels
of every pulmonary function measure, adjust-
ing for age and height. After controlling for
the additional personal and socioeconomic
covariates, the highest cotinine tertile was
associated with decreased FEV1 (–116 mL;
95% CI, –154 to –77 mL), FVC (–143 mL;
CI, –187 to –99 mL), and FEV1/FVC ratio
(–1.82%; CI, –2.25% to –1.39%).
ETS exposure and pulmonary function
among nonsmoking adults with asthma.
Among male adults with asthma, the highest
cotinine tertile was associated with a lower
age- and height-adjusted FEV1/FVC ratio,
even after controlling for race/ethnicity, previ-
ous smoking history, and socioeconomic indi-
cators (Table 5). The medium cotinine tertile
was related to a higher FEV1 and FVC.
However, I found no relation between the
highest cotinine tertile and either measure. As
a continuous variable, cotinine level was also
not related to FEV1 or FVC.
In the female stratum, the overall pattern
of results suggested a relationship between
greater cotinine levels and lower pulmonary
function. After controlling for all covariates,
the highest cotinine tertile was associated with
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Table 3. ETS exposure and pulmonary function among nonsmoking adult participants in NHANES III shown by change in mean residual value (95% CI).
FEV1 (mL) FVC (mL) FEV1/FVC ratio (%)
Adjusted for age Adjusted for age  Adjusted for age
Sex/cotinine levela and heightb Multivariateb and height Multivariate and height Multivariate
Malesc
L— — — — — —
M 75 (–4 to 153) 78 (4 to 153) 86 (–6 to 179) 94 (5 to 182) –0.57 (–0.88 to –0.26) –0.53 (–0.80 to –0.26)
H 22 (–38 to 83) 47 (–11 to 106) –17 (–96 to 61) 19 (–56 to 94) –1.27 (–1.62 to –0.92) –1.18 (–1.49 to –0.87)
Cont –15 (–36 to 6) –2.7 (–21 to 15) –26 (–58 to 6) –9 (–36 to 17) –0.24 (–0.32 to –0.16) –0.22 (–0.32 to –0.12)
Femalesd
L— — — — — —
M –53 (–96 to –9) –38 (–81 to 6) –55 (–103 to –6) –37 (–86 to 11) –0.64 (–1.05 to –0.33) –0.61 (–0.96 to –0.26)
H –142 (–189 to –95) –100 (–143 to –56) –169 (–221 to –117) –119 (–168 to –69) –1.80 (–2.21 to –1.39) –1.77 (–2.18 to –1.36)
Cont –46 (–60 to –33) –38 (–51 to –25) –51 (–66 to –37) –41 (–55 to –27) –0.40 (–0.56 to –0.24) –0.42 (–0.58 to –0.26)
aCotinine analyzed as tertiles: L, lowest (0–0.093 ng/mL); M, medium (> 0.093 to 3.16 ng/mL); H, highest (> 3.16 ng/mL); Cont, continuous variable. bResidual values calculated as observed
minus expected values. Expected values derived from Crapo equations based on age, sex, and height; multivariate models also adjust for educational attainment, low income, previous
smoking history (if any), and race/ethnicity. cNo. participants = 4,491; estimated population = 49,259,167. dNo. participants = 6,090; estimated population = 62,977,009.decreased FEV1 (–261 mL; 95% CI, –492 to
–30 mL), FVC (–291 mL; 95% CI, –601 to
20 mL), and FEV1/FVC ratio (–1.6%; 95%
CI, –3.3% to 0.19%). The conﬁdence inter-
val for FVC and FEV1/FVC did not exclude
a lack of relationship. When considered as a
continuous variable, greater cotinine level was
statistically associated with a lower
FEV1/FVC ratio (–0.74 for each 1 ng/mL
cotinine increment; 95% CI, –1.4 to –0.74).
To further evaluate the association
between ETS exposure and pulmonary func-
tion among adults with asthma, I repeated
the analysis using the Hankinson spirometric
reference values derived from NHANES III
participants with no lifetime smoking his-
tory, no asthma, and no other respiratory
symptoms or conditions. I found no statisti-
cal association between cotinine level and
any pulmonary function measurement
among men (Table 6). In the female stra-
tum, the highest cotinine tertile was associ-
ated with decreased FEV1 (–250 mL; 95%
CI, –487 to –14 mL), FVC (–275 mL; 95%
CI, –583 to 34 mL), and FEV1/FVC ratio
(–1.9%; 95% CI, –6.1% to 2.2%).
ETS exposure at home and work. Because
the pulmonary function results appeared to
differ by sex, I examined the relationhip
between sex and self-reported location of ETS
exposure. In the entire nonsmoking sample, a
similar proportion of males (14.3%) and
females (14.9%) indicated home ETS expo-
sure (p = 0.51). Nearly twice as many male
subjects reported work exposure (27.7% vs.
15.2%, p < 0.0001). Among adults with
asthma, I found also no statistical difference
in self-reported home exposure between male
(18.8%) and female respondents (14.3%; p =
0.41). A greater proportion of male subjects
with asthma reported exposure to ETS at
work (35.9% vs. 20.6%, p = 0.07).
In the male stratum of the entire non-
smoking sample and the asthma sample, the
medium cotinine tertile was statistically asso-
ciated with greater mean FEV1. When I
added location of exposure to these multi-
variate linear regression analyses, the medium
cotinine tertile was less strongly associated
with FEV1 in the entire nonsmoking group
(coefficient decreased by 17%) and the
asthma group (coefﬁcient decreased by 5%).
Discussion
ETS exposure was widespread among non-
smoking U.S. adults, with no evidence of
selective avoidance by persons with current
asthma. Among nonsmoking women, ETS
exposure was associated with a moderate
reduction in pulmonary function. In the
subgroup of women with asthma, ETS expo-
sure was also related to decreased pulmonary
function. Compared to the general popula-
tion of nonsmoking adults, the reduction in
pulmonary function appeared even greater
among adult women with asthma (e.g., FEV1
decrement, –261 vs. –100 mL). In men,
however, I found no evidence that ETS expo-
sure was related to decreased pulmonary
function among nonsmoking adults or those
with asthma. These results support a deleteri-
ous effect of ETS on the respiratory health of
women, especially those with asthma.
A significant proportion of U.S. adults
report exposure to ETS, ranging from 37%
to 63% (1–3). A previous report from
NHANES III documented that most chil-
dren and adults had detectable serum cotinine
levels, indicating ETS exposure (2). Because
adults with asthma have a chronic respiratory
disease, they might be expected to avoid ETS
exposure. Few previous studies have tested
this assumption. In a cohort of adults with
asthma living in northern California, 46%
reported recent ETS exposure (25). Among
adult health maintenance organization mem-
bers with asthma, 38% indicated regular ETS
exposure (8). Neither study compared sub-
jects with asthma to a general population ref-
erent group. A population-based study from
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Table 5. ETS exposure and pulmonary function among nonsmoking adults with asthma participating in NHANES III shown by change in mean residual value (95% CI).
FEV1 (mL) FVC (mL) FEV1/FVC ratio (%)
Adjusted for age Adjusted for age  Adjusted for age
Sex/cotinine levela and heightb Multivariateb and height Multivariate and height Multivariate
Malesc
L— — — — — —
M 572 (91 to 1,053) 569 (78 to 1,060) 222 (–103 to 547) 222 (–92 to 536) –0.58 (–1.9 to 0.72) –0.54 (–1.8 to 0.73)
H 209 (–224 to 642) 242 (–169 to 653) –84 (–424 to 256) –30 (–331 to 271) –1.9 (–3.1 to –0.68) –1.6 (–2.8 to –0.30)
Cont –85 (–197 to 28) –74 (–162 to 14) –42 (–167 to 84) –24 (–107 to 59) –0.76 (–1.1 to –0.41) –0.74 (–0.95 to –0.53)
Femalesd
L— — — — — —
M –68 (–288 to 152) –87 (–278 to 104) –46 (–288 to 195) –63 (–278 to 152) –0.40 (–2.0 to 1.2) –0.46 (–2.0 to 1.1)
H –232 (–457 to –8) –261 (–492 to –30) –276 (–603 to 51) –291 (–601 to 20) –1.4 (–3.0 to 0.31) –1.6 (–3.3 to 0.19)
Cont –58 (–172 to 56) –52 (–157 to 53) –90 (–219 to 39) –77 (–186 to 32) –0.74 (–1.29 to –0.19) –0.74 (–1.4 to –0.74)
aCotinine analyzed as tertiles: L, lowest (0–0.093 ng/mL); M, medium (> 0.093– 3.16 ng/mL); H, highest (> 3.16 ng/mL); Cont, continuous variable. bResidual values calculated as observed
minus expected values. Expected values derived from Crapo equations based on age, sex, and height. Multivariate models also adjust for educational attainment, low income, previous
smoking history (if any), and race/ethnicity. cNo. participants = 145; estimated population = 1,646,890. dNo. participants = 295; estimated population = 3,234,235.
Table 4. ETS exposure and pulmonary function among adult participants in NHANES III who never smoked shown by change in mean residual value (95% CI).
FEV1 (mL) FVC (mL) FEV1/FVC ratio (%)
Adjusted for age Adjusted for age  Adjusted for age
Sex/cotinine levela and heightb Multivariateb and height Multivariate and height Multivariate
Malesc
L— — — — — —
M 114 (7 to 221) 130 (29 to 230) 134 (–8 to 277) 157 (26 to 288) –0.49 (–0.90 to 0.078) –0.45 (–0.84 to –0.058)
H4  (–78 to 87) 45 (–32 to 120) –38 (–148 to 73) 20 (–84 to 124) –1.17 (–1.56 to –0.78) –1.06 (–1.47 to –0.65)
Cont –34 (–60 to –9) –19 (–39 to 0) –45 (–95 to 5) –23 (–63 to 17) –0.23 (–0.35 to –0.11) –0.18 (–0.28 to –0.08)
Femalesd
L— — — — — —
M –43 (–84 to –1) –24 (–66 to 18) –56 (–111 to –0.5) –33 (–87 to 22) –0.70 (–1.09 to –0.31) –0.60 (–0.97 to –0.23)
H –168 (–209 to –126) –116 (–154 to –77) –209 (–256 to –162) –143 (–187 to –99) –2.01 (–2.42 to –1.60) –1.82 (–2.25 to –1.39)
Cont –58 (–78 to –37) –44 (–63 to –25) –65 (–88 to –42) –48 (–69 to –27) –0.54 (–0.71 to –0.36) –0.51 (–0.67 to –0.35)
aCotinine analyzed as tertiles: L, lowest (0–0.093 ng/mL); M, medium (> 0.093–3.16 ng/mL); H, highest (> 3.16 ng/mL); Cont, continuous variable. bResidual values calculated as observed
minus expected values. Expected values derived from Crapo equations based on age, sex, and height; multivariate models also adjust for educational attainment, low income, previous
smoking history (if any), and race/ethnicity. cNo. participants = 2,567; estimated population = 28,631,542. dNo. participants = 4,858; estimated population = 46,916,128.Canada found that 42% of nonsmoking chil-
dren and adults with asthma reported ETS
exposure during the previous 24 hr, com-
pared with 32% of the general population
(26). In a nationally representative sample of
U.S. adults, the present analysis found no evi-
dence that adults with asthma have a lower
prevalence or intensity of ETS exposure.
In children, more than 30 studies have
linked domestic ETS exposure with
decreased development of lung function (1).
Among adults, the impact of ETS on pul-
monary function has been less clear. In sev-
eral studies, self-reported ETS exposure was
associated with decreased FEV1, FVC, or
FEV1/FVC ratio (27–33). Supporting these
deleterious effects of ETS, we found an
increase in pulmonary function among 53
bartenders after reduction in workplace ETS
exposure during an 8-week period (34). Two
other observational studies demonstrated a
relation between ETS exposure and decreased
forced expiratory ﬂow, midexpiratory phase
(FEF25%-75%), but not FEV1 or FVC
(35,36). Other investigators have found no
consistent relationship between ETS expo-
sure and pulmonary function in adults
(37–46).
Nearly all previous studies that examined
the effects of ETS exposure on adult pul-
monary function have relied on self-reported
exposure assessment. Ascertainment of ETS
exposure by self-report is potentially subject
to information bias, which limits interpreta-
tion of these studies. For example, persons
with impaired pulmonary function might be
more likely to remember and report ETS
exposure, whereas unaffected persons might
underreport ETS exposure. Alternatively,
adults who develop a pulmonary function
decrement from ETS exposure or other
causes may subsequently avoid ETS expo-
sure, attenuating the observed impact of
ETS on pulmonary function in a cross-sec-
tional analysis. Furthermore, nondifferential
misclassification of exposure status would
likely reduce the estimated effect of ETS
exposure.
In one of the few other studies using
objective ETS exposure assessment in adults,
Carey et al. (47) demonstrated a cross-sec-
tional association between greater cotinine
levels and decreased FEV1 in British adults
(105-mL decrement in the highest quintile).
In a smaller study of 301 Scottish adults,
serum cotinine level, as a continuous vari-
able, was not related to pulmonary function
(33). Another small study found no impact
of ETS exposure, conﬁrmed by urinary coti-
nine measurement, on peak expiratory ﬂow
variability among healthy nonsmoking
adults (48). The present population-based
study, which uses a biomarker to minimize
misclassification of ETS exposure, further
establishes the link between ETS exposure
and pulmonary function impairment.
Although adults with asthma comprise a
potentially susceptible population, the
impact of ETS exposure on their pulmonary
function has not been well characterized. In a
population-based sample of Swiss adults with
asthma, self-reported workplace ETS expo-
sure was associated with decreased FEV1
(4.8% decrement) (43). Domestic ETS expo-
sure was not examined and ETS biomarkers
were not measured. Other investigators
examined the impact of self-reported ETS
exposure on 200 adults with asthma who
were attending a university-based chest clinic
in India (7). Compared with unexposed
patients, adult asthmatics reporting ETS
exposure had lower FEV1 (68.7% vs. 80.8%
of predicted) and FEV1/FVC (63.5% vs.
78.4%). Based on data from a study in
Tuscon, Arizona, there was no apparent rela-
tionship between ETS exposure and peak
expiratory flow among adults with asthma
(49). The present study provides important
information that supports the relationship
between ETS exposure and pulmonary func-
tion decrement among women with asthma.
Because ETS contains potent respiratory
irritants, exposure may adversely affect
bronchial smooth muscle tone or induce air-
way inflammation in adults with asthma
(1). Controlled chamber exposure studies
support the biologic plausibility of ETS-
related asthma exacerbation. After short-
term exposure of 1–3 hr, many asthmatics
experience a decline in FEV1 (50–53).
Pretreatment with bronchodilators appears
to prevent the acute decline in FEV1 in pre-
viously reactive subjects (54). Other studies,
however, have found no effect of acute
chamber ETS exposure on lung function in
asthmatic subjects (55,56). Interpretation of
these controlled exposure studies is limited
by small sample size, variable subject inclu-
sion criteria, and variation in chamber expo-
sure methodology. Nonetheless, these
experimental studies support the plausibility
of ETS-induced pulmonary function
decline in adults with asthma.
The analysis is subject to certain limita-
tions. Using this cross-sectional data, the
analysis could not separate the acute from
chronic effects of ETS exposure on pul-
monary function. Previous studies have doc-
umented both acute (57) and chronic effects
(1) of ETS exposure on pulmonary function.
Moreover, cotinine reflects ETS exposure
during the past 3–4 days. To assess the
chronic impact of ETS exposure on pul-
monary function requires the assumption
that current exposure is a good proxy for
previous exposure. Using a survey-based
ETS exposure instrument, our group found
that self-reported ETS exposure was stable
over a 6–7 month period (25). Even so, the
possibility of changing exposure status over
time cannot be excluded.
Because this study was cross-sectional, the
causal pathway cannot be clearly deﬁned in all
cases. The association between ETS exposure
and decreased pulmonary function in women
cannot be plausibly explained by a reverse
chain of events, that impaired pulmonary func-
tion causes women to increase their ETS expo-
sure. In men, however, the relationship
between ETS exposure and higher pulmonary
function in the medium cotinine tertile could
be explained by selective ETS avoidance (i.e.,
that lower pulmonary function or associated
respiratory symptoms cause men to decrease
their exposure). Supporting this idea, men were
more likely than women to report work expo-
sure, a potentially more avoidable exposure
location. Moreover, controlling for exposure
location attenuated this relation between ETS
exposure and higher pulmonary function.
Despite extensive evidence that ETS has
serious long-term health consequences such
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Table 6. The association between ETS exposure and pulmonary function among adults with asthma, using
predicted spirometry values from NHANES III participants who never smoked and had no respiratory
symptoms or conditions, shown by change in mean residual value (95% CI).a
Sex/cotinine levelb FEV1 (mL) FVC (mL) FEV1/FVC ratio
Malesc
L ———
M 423 (–72 to 918) 95 (–241 to 431) 7.6 (–3.2 to 18.4)
H 90 (–385 to 565) –166 (–509 to 178) 3.7 (–6.1 to 13.5)
Cont –47 (–131 to 37) 30 (–64 to 124) –1.6 (–3.4 to 0.18)
Femalesd
L— — —
M –110 (–314 to 95) –135 (–340 to 71) –0.5 (–4.4 to 3.4)
H –250 (–487 to –14) –275 (–583 to 34) –1.9 (–6.1 to 2.2)
Cont –44 (–163 to 75) 53 (–64 to 171) –0.23 (–2.0 to 1.5)
aResidual values were calculated as observed minus expected values; expected values were derived from Hankinson
equations based on age, sex, race/ethnicity (white, African American, Mexican American), and height. All results were
based on multivariate models that also adjust for age, educational attainment, low income, and previous smoking history
(if any). The estimated population excludes 17 subjects who did not report race/ethnicity as white, African American or
black, or Mexican American. bCotinine analyzed as tertiles: L, lowest (0–0.109 ng/mL); M, medium (> 0.109–3.68 ng/mL); H,
highest (> 3.68 ng/mL); Cont, continuous variable. cNo. participants = 141; estimated population = 1,565,460. dNo. partici-
pants = 282; estimated population = 2,971,841.as lung cancer and cardiovascular disease,
exposure remains widespread. Persons who
actively smoke may resist efforts to curtail
their behavior. Many members of the public
also do not believe that ETS poses a threat to
their health. Among bartenders working in
San Francisco, California, our group found
that 21% expressed the belief that ETS
exposure has no adverse effect on their per-
sonal health (34). Business owners, especially
restaurant, bar, and hotel proprietors, are
concerned that public smoking prohibition
may result in economic losses. Taken
together, these factors constitute a signiﬁcant
barrier to establishing smoke-free public
places. The observed association between
ETS exposure and pulmonary function
decrement should provide further impetus
for public policies aimed at creating smoke-
free environments.
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